Human epidermal growth factor receptor 2 (HER2) amplification/overexpression is an
effective therapeutic target in breast and gastric cancer. Although HER2 positivity has been …

Protein levels and function are poorly predicted by genomic and transcriptomic analysis of
patient tumours. Therefore, direct study of the functional proteome has the potential to …

Urothelial carcinoma (UC) is the fourth most prevalent cancer amongst males worldwide.
While patients with non-muscle-invasive disease have a favorable prognosis, 25% of UC …

Purpose Somatic mutations and copy number variation in the ERBB family are frequent in
urothelial carcinoma (UC) and may represent viable therapeutic targets. We studied whether …

Background This study assessed the human epidermal growth factor receptor-2 (HER2)
protein expression and its relationship with gene amplification in invasive bladder …

Human epidermal growth factor receptor 2 (HER2) is an important biomarker for breast and
gastric cancer prognosis and patient treatment decisions. HER2 positivity, as defined by IHC …

Human epidermal growth factor receptor-2 (HER2) is a well-recognized growth-promoting
factor in cancer, although its application to urothelial carcinoma has been limited because of …

We evaluated primary tumors from two cohorts, Spain (N= 111) and Greece (N= 102), for
patients who were treated with platinum‐based chemotherapy. Patients were tested for …

Comprehensive molecular analyses of urothelial bladder cancer (UBC) have defined distinct
subtypes with potential therapeutic implications. In this study, we focused on micropapillary …

Background The frequency of HER2 overexpression in bladder cancer is reported as 9%-
61%. HER2 alteration correlates with aggressive disease in bladder cancer. Traditional anti …